These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 25245423

  • 1. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
    Kharbanda A, Rajabi H, Jin C, Alam M, Wong KK, Kufe D.
    Oncotarget; 2014 Oct 15; 5(19):8893-905. PubMed ID: 25245423
    [Abstract] [Full Text] [Related]

  • 2. Targeting the oncogenic MUC1-C protein inhibits mutant EGFR-mediated signaling and survival in non-small cell lung cancer cells.
    Kharbanda A, Rajabi H, Jin C, Tchaicha J, Kikuchi E, Wong KK, Kufe D.
    Clin Cancer Res; 2014 Nov 01; 20(21):5423-34. PubMed ID: 25189483
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.
    Bouillez A, Rajabi H, Pitroda S, Jin C, Alam M, Kharbanda A, Tagde A, Wong KK, Kufe D.
    Cancer Res; 2016 Mar 15; 76(6):1538-48. PubMed ID: 26833129
    [Abstract] [Full Text] [Related]

  • 4. MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition.
    Rajabi H, Alam M, Takahashi H, Kharbanda A, Guha M, Ahmad R, Kufe D.
    Oncogene; 2014 Mar 27; 33(13):1680-9. PubMed ID: 23584475
    [Abstract] [Full Text] [Related]

  • 5. MUC1-C Induces the LIN28B→LET-7→HMGA2 Axis to Regulate Self-Renewal in NSCLC.
    Alam M, Ahmad R, Rajabi H, Kufe D.
    Mol Cancer Res; 2015 Mar 27; 13(3):449-60. PubMed ID: 25368430
    [Abstract] [Full Text] [Related]

  • 6. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
    Jin D, Guo J, Wu Y, Du J, Wang X, An J, Hu B, Kong L, Di W, Wang W.
    Theranostics; 2019 Mar 27; 9(7):2036-2055. PubMed ID: 31037155
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.
    Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.
    Oncogene; 2014 Jun 26; 33(26):3422-31. PubMed ID: 23912457
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
    Chen J, Bi H, Hou J, Zhang X, Zhang C, Yue L, Wen X, Liu D, Shi H, Yuan J, Liu J, Liu B.
    Cell Death Dis; 2013 Sep 26; 4(9):e814. PubMed ID: 24071646
    [Abstract] [Full Text] [Related]

  • 11. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
    Sunaga N, Shames DS, Girard L, Peyton M, Larsen JE, Imai H, Soh J, Sato M, Yanagitani N, Kaira K, Xie Y, Gazdar AF, Mori M, Minna JD.
    Mol Cancer Ther; 2011 Feb 26; 10(2):336-46. PubMed ID: 21306997
    [Abstract] [Full Text] [Related]

  • 12. Tumor-suppressive effects of microRNA-181d-5p on non-small-cell lung cancer through the CDKN3-mediated Akt signaling pathway in vivo and in vitro.
    Gao LM, Zheng Y, Wang P, Zheng L, Zhang WL, Di Y, Chen LL, Yin XB, Tian Q, Shi SS, Xu SF.
    Am J Physiol Lung Cell Mol Physiol; 2019 May 01; 316(5):L918-L933. PubMed ID: 30628487
    [Abstract] [Full Text] [Related]

  • 13. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
    Kitai H, Ebi H, Tomida S, Floros KV, Kotani H, Adachi Y, Oizumi S, Nishimura M, Faber AC, Yano S.
    Cancer Discov; 2016 Jul 01; 6(7):754-69. PubMed ID: 27154822
    [Abstract] [Full Text] [Related]

  • 14. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W, Ping W, Tian Y, Zou W, Liu J, Zu Y.
    Cell Physiol Biochem; 2018 Jul 01; 51(5):2160-2171. PubMed ID: 30522099
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
    Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J.
    BMC Med Genomics; 2010 Jun 30; 3():26. PubMed ID: 20591134
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
    Cai WK, Hu J, Li T, Meng JR, Ma X, Yin SJ, Zhao CH, He GH, Xu GL.
    Eur J Cancer; 2014 Apr 30; 50(6):1195-206. PubMed ID: 24447834
    [Abstract] [Full Text] [Related]

  • 19. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN, Rowley S, Archibald HL, Gomez-Caraballo M, Siddiqui FM, Ji F, Jung J, Light M, Lee JS, Debussche L, Sidhu S, Sadreyev RI, Watters J, Engelman JA.
    Oncogene; 2017 Nov 23; 36(47):6581-6591. PubMed ID: 28783173
    [Abstract] [Full Text] [Related]

  • 20. Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase.
    Scrima M, De Marco C, Fabiani F, Franco R, Pirozzi G, Rocco G, Ravo M, Weisz A, Zoppoli P, Ceccarelli M, Botti G, Malanga D, Viglietto G.
    PLoS One; 2012 Nov 23; 7(2):e30427. PubMed ID: 22363436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.